Want to see AU:1AI full AI Analyst Report?
Living Cell Technologies (1AI) AI Stock Analysis
Top Page
Living Cell Technologies
(ASX:1AI)
The low overall score is driven primarily by weak financial performance, with no revenue, ongoing losses, and increased cash burn, offset only modestly by a debt-free balance sheet; neutral technical signals and a speculative valuation with negative earnings and no dividend further limit the stock’s attractiveness.
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 7.10M
- Dividend Yield
- ―
- Average Volume (3M)
- 634.75K
- Price to Earnings (P/E)
- -5.7
- Beta (1Y)
- 0.15
- Revenue Growth
- ―
- EPS Growth
- -200.00%
- Country
- Australia
- Employees
- 48
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Living Cell Technologies Business Overview & Revenue Model
Company Description
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily c...
How the Company Makes Money
null
Living Cell Technologies Financial Statement Overview
Summary
Pre-revenue profile with persistent operating losses and negative cash flow, partly offset by a debt-free balance sheet and positive equity.
Income Statement
18Very NegativeBalance Sheet
52NeutralCash Flow
22Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2024 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -557 | -743 |
| EBITDA | -2.04M | -3.14M | -2.10M | -1.54M | -2.13M | -2.38M |
| Net Income | -2.37M | -2.71M | -2.10M | -802.96K | -2.11M | -1.96M |
Balance Sheet | ||||||
| Total Assets | 4.44M | 4.44M | 5.49M | 2.40M | 4.21M | 4.27M |
| Cash, Cash Equivalents and Short-Term Investments | 3.94M | 3.94M | 3.11M | 2.32M | 6.13M | 7.24M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 176.72K | 176.72K | 178.45K | 169.76K | 449.86K | 239.26K |
| Stockholders Equity | 4.26M | 4.26M | 3.01M | 2.23M | 3.76M | 4.03M |
Cash Flow | ||||||
| Free Cash Flow | -2.00M | -2.60M | -1.52M | -785.25K | -1.99M | -2.05M |
| Operating Cash Flow | -2.00M | -2.60M | -1.52M | -785.25K | -1.99M | -2.04M |
| Investing Cash Flow | 1.90M | 1.10M | -277.44K | 450.00K | 0 | 39.50K |
| Financing Cash Flow | 2.29M | 4.22M | 523.00K | -3,000 | 1.85M | 4.69M |
Living Cell Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:1AI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 42.07 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:1AI.
Living Cell Technologies Peers Comparison
Overall Rating
AU:MSB64Neutral
AU:CMB51Neutral
AU:OCC50Neutral- AU:1AI43Neutral
AU:CYP42Neutral
AU:TRP32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MSB | 64Neutral | AUD 2.94B | -35.83 | -10.06% | ― | 555.67% | 49.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:CMB | 51Neutral | AUD 11.77M | -1.59 | -247.44% | ― | -4.24% | 33.39% |
| AU:OCC | 50Neutral | AUD 149.82M | -10.38 | -36.83% | ― | 51.07% | -47.63% |
| AU:1AI | 43Neutral | AUD 20.28M | -5.71 | -132.20% | ― | ― | -200.00% |
| AU:CYP | 42Neutral | AUD 4.02M | -0.31 | -617.89% | ― | ― | 13.67% |
| AU:TRP | 32Underperform | AUD 5.06M | -1.07 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:1AI | Living Cell Technologies Ltd. | 0.01 | 0.00 | 0.00% | |
| AU:CYP | Cynata Therapeutics Limited | 0.01 | -0.22 | -94.78% | |
| AU:MSB | Mesoblast Limited | 2.26 | -0.22 | -8.87% | |
| AU:OCC | Orthocell Ltd | 0.55 | -0.64 | -53.78% | |
| AU:TRP | Tissue Repair Ltd | 0.10 | -0.24 | -71.21% | |
| AU:CMB | Regeneus Ltd. | 0.40 | -0.09 | -19.19% |
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals Lapses 10 Million Performance Rights After Unmet Conditions
Algorae Pharmaceuticals Limited has notified the ASX of the cessation of 10,000,000 performance rights after the underlying conditions failed to be met or became incapable of being satisfied. The lapse of these conditional securities reduces the comp...
Algorae Pharmaceuticals Files ASX Corporate Governance Statement for 2026
Algorae Pharmaceuticals has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with key ASX Corporate Governance Council principles. The statement, approved as of 31 August 2026 and published on th...
Algorae Pharmaceuticals Losses Deepen as Commercial Operations Expand
Algorae Pharmaceuticals Limited reported a sharp deterioration in its full-year financial performance to 30 June 2026, with total revenue and other income falling 45% to $77,667. The group booked no service revenue and again paid no dividends, unders...
Algorae bolsters board with Nasdaq pharmaceutical chairman Troy Valentine
Algorae Pharmaceuticals has appointed Nasdaq pharmaceutical chairman Troy Valentine as a Non-Executive Director, effective 14 July 2026, as part of a broader board renewal program. His appointment follows the resignation of director Brad Dilkes and w...
Algorae Pharmaceuticals Issues 2 Million New Shares Under Cleansing Notice
Algorae Pharmaceuticals has issued 2,000,000 fully paid ordinary shares on 6 July 2026, notifying the market via a cleansing notice under section 708A(5)(e) of the Corporations Act. The company states that the shares were issued without a disclosure...
Algorae Pharmaceuticals Seeks ASX Quotation for 2 Million New Shares
Algorae Pharmaceuticals Limited has applied for quotation of 2,000,000 ordinary fully paid shares on the Australian Securities Exchange. The new securities, to be issued under the ASX code 1AI on July 6, 2026, expand the company’s listed capita...
AlgoraeOS v2 Wins Independent Validation for Cancer Drug Synergy Predictions
Algorae Pharmaceuticals has reported positive independent preclinical validation of its AlgoraeOS v2 drug-combination prediction platform at the Peter MacCallum Cancer Centre. The study evaluated 24 CBD drug combinations across four cancer cell lines...
Algorae Wins NSW Health Hospital Supply Deal in Key Commercial Milestone
Algorae Pharmaceuticals has secured a public hospital supply contract with NSW Health following a competitive tender, marking a significant commercial milestone for its AlgoraeRx division. The initial three-year agreement, with two optional one-year...
Algorae Pharmaceuticals appoints joint company secretaries as it advances AI-driven drug strategy
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical group listed on the ASX that combines advanced drug-combination discovery with a growing commercial medicines business. Its AlgoraeOS platform uses machine learning to identify synergistic d...
Algorae Joins Sovereign AI Infrastructure as Healthcare Launch Partner
Algorae Pharmaceuticals has been selected as a foundation participant and the healthcare and life sciences launch partner for the new Sovereign AI Infrastructure initiative, led by AgenticScale.ai and powered by NVIDIA-accelerated technology. The pro...
Algorae Pharmaceuticals switches auditors to address independence concerns
Algorae Pharmaceuticals has appointed PKF Perth as its new external auditor, following the resignation of PKF Brisbane Audit and consent from the Australian Securities and Investments Commission. The change is motivated by auditor independence consid...
Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice
Algorae Pharmaceuticals has issued a new tranche of fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the small-scale offering provisions of the Corporations Act. The company con...
Algorae Pharmaceuticals Plans Placement of 2 Million New Shares
Algorae Pharmaceuticals has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares under a new placement or similar capital-raising structure. The securities are expected to be issued on 16 June 2026, signalling an additio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026